Benefit-risk ratios in the assessment of the clinical evidence of a new therapy

Controlled Clinical Trials

Volumn 18, Issue 2, 1997, Pages 121-130

  Willan, Andrew R ^a   O'Brien, Bernie J ^a,b   Cook, Deborah J ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b CENTRE FOR EVALUATION OF MEDICINES   (Canada)

Author keywords

benefit risk ratio; side effects; therapy

Indexed keywords

HEPARIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLEEDING; CLINICAL TRIAL; DRUG EFFICACY; HEART INFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; RISK BENEFIT ANALYSIS; SURVIVAL; THEORETICAL STUDY;

CONFIDENCE INTERVALS; CONTROLLED CLINICAL TRIALS; DECISION MAKING; HUMANS; MODELS, STATISTICAL; MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT (HEALTH CARE); PLASMINOGEN ACTIVATORS; RESEARCH DESIGN; STREPTOKINASE; SURVIVAL ANALYSIS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0030987417     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(96)00092-X     Document Type: Article

References (31)

1. Guyatt GH, Sackett DL, Cook DJ for the Evidence-based Medicine Working Group. Users' Guides to the Medical Literature: How to use an article about therapy or prevention. A: Are the results of the study valid? JAMA 1993; 270:2598-2601.
2. Guyatt GH, Sackett DL, Cook DJ for the Evidence-based Medicine Working Group. Users' Guides to the Medical Literature: How to use an article about therapy or prevention. B: What were the results and will they help me in caring for my patients? JAMA 1994; 271:59-63.
3. McNeil BJ, Weichselbaum R, Pauker S. Tradeoffs between quality and quantity of life in laryngeal cancer. N Engl J Med 1981; 305:982-987.
4. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988; 318:1728-1733.
5. The GUSTO Investigators: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329:673-682.
6. Chelluri L, Sirio CA, Angus DC. Thrombolytic therapy for acute myocardial infarction: GUSTO criticized. N Engl J Med 1994; 330:505.
7. Friedman HS. Thrombolytic therapy for acute myocardial infarction: GUSTO criticized. N Engl J Med 1994; 330:506.
8. Bloomfield P. Linear transformations for multivariate binary data. Biometrics 1974; 30:609-617.
9. O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics 1984; 40:1079-1087.
10. Pocock SJ, Geller NL, Tsiatis AA. The analysis of multiple endpoints in clinical trials. Biometrics 1987; 43:487-498.
11. Lefkopoulou M, Moore D, Ryan L. The analysis of multiple correlated binary outcomes: Application to rodent teratology experiments. JASA 1989; 84:810-815.
12. Tang D-I, Gnecco C, Geller NL. Design of group sequential clinical trials with multiple endpoints. JASA 1989; 84:776-779.
13. Lehmacher W, Wassmer G, Reitmeir P. Procedures for two-sample comparisons with multiple endpoints controlling and experimentwise error rate. Biometrics 1991; 47:511-521.
14. Chuang-Stein C, Mohberg NR. Organization and analysis of safety data using a multivariate approach. Stat Med 1992; 11:1075-1089.
15. Lefkpoulou M, Ryan L. Global tests for multiple binary outcomes. Biometrics 1993; 49:975-988.
16. Tang D-I, Geller NL, Pocock SJ. On the design and analysis of randomized clinical trials with multiple endpoints. Biometrics 1993; 49:23-30.
17. Legler JM, Ryan LM, Harvey EA, Holmes LB. Anticonvulsant teratogenesis: 2. Statistical methods for multiple birth outcomes. Teratology 1994; 50:74-79.
18. Tsai K-T, Koziol JA. Assessing multiple endpoints with ordered alternatives. Commun Statist-Theory Meth 1994; 23:533-544.
19. Brown C, Fears TR. Exact significance levels for multiple binomial testing with application to carcinogenicity screens. Biometrics 1981; 37:763-774.
20. Westfall PH, Young SS. p Value adjustments for multiple tests in multivariate binomial models. JASA 1989; 84:780-786.
21. Gail M. Value systems for comparing two independent multinomial trials. Biometrika 1974; 61:91-100.
22. Willan AR, Pater JL. Hypothesis testing and sample size for bivariate binomial response in the comparison of two groups. J Chron Dis 1985; 38:603-608.
23. Jennison C, Turnbull BW. Group sequential tests for bivariate response: Interim analyses of clinical trials with both efficacy and safety endpoints. Biometrics 1993; 49:741-753.
24. Chuang-Stein C. A new proposal for benefit-less risk analysis in clinical trials. Controlled Clin Trials 1994; 15:30-43.
25. Guyatt GH, Jaeschkle RZ, Heddle N, Cook DJ, Shannon H, Walter S. Basic statistics for clinicians: Interpreting study results: Confidence intervals. Can Med Assoc J 1995; 152:169-173.
26. Goodman SN, Berlin JA. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. Ann Intern Med 1994; 121:200-206.
27. Borenstein M. The case for confidence intervals in controlled clinical trials. Controlled Clin Trials 1994; 15:411-428.
28. Braitman LE. Confidence intervals assess both clinical significance and statistical significance. Ann Intern Med 1991; 114:515-517.
29. O'Brien BJ, Drummond MF, Labelle RJ, Willan AR. In search of power and significance: Issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care 1994; 32:150-163.
30. Efron B. Bootstrap confidence intervals for a class of parametric problems. Biometrika 1985; 72:45-58.
31. Fieller EC. Some problems in interval estimation (with discussion). J R Stat Soc, Series B 1954; 16:175-185.